Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01622088 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Extension Study of Dexpramipexole in ALS

A Phase 3 study, sponsored by Knopp Biosciences.

Terminated
Registry status
Phase 3
Development phase
616
Enrollment target

NCT01622088: Clinical Trial Phase 3 study, sponsored by Knopp Biosciences.

NCT01622088 is a Phase 3 study that was terminated before completion, run by Knopp Biosciences. The registered enrollment target is 616 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01622088, a Phase 3 study, was terminated before completion, sponsored by Knopp Biosciences.

TERMINATED
Registry status
Phase 3
Development phase
616 participants
Enrollment target

Study Summary

The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.

Primary Outcome

The number of subjects who reported an adverse event during the study

Interventions

  • DRUG Dexpramipexole

Trial Details

FieldValue
Enrollment Target 616 participants
Start Date 2012-06
Est. Completion 2013-02
Phase Phase 3
Knopp Biosciences

12 total trials

Why NCT01622088 stopped before completion

NCT01622088 is an interventional study that assigns participants to a tested intervention. The registered 616 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 1 intervention - of which Dexpramipexole is the first listed.

NCT01622088 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01622088 about?

NCT01622088 is a clinical study titled "Phase 3 Extension Study of Dexpramipexole in ALS". The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.

What is the current status of trial NCT01622088?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 616 participants. The study started on 2012-06. Estimated completion is 2013-02.

What interventions are being tested in trial NCT01622088?

The interventions under investigation include: Dexpramipexole (DRUG).

Who is sponsoring clinical trial NCT01622088?

This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01622088's enrollment target sits among peer trials

616 593rd of 2000 higher than 1,408 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04813185 · 616 participants · NA

    Preventing Retaliatory Gun Violence in Violently Injured Adults

  • NCT06105957 · 616 participants · NA

    Optimal Digital Weight Loss Treatment for Rural Individuals

  • NCT06162221 · 616 participants · Phase 1

    Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • NCT02610179 · 617 participants · NA

    Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01622088, the US trial registry maintained by the National Library of Medicine. NCT01622088 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.